---
document_datetime: 2025-12-02 06:42:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/stimufend.html
document_name: stimufend.html
version: success
processing_time: 0.1036964
conversion_datetime: 2025-12-27 13:21:28.423844
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Stimufend

[RSS](/en/individual-human-medicine.xml/67542)

##### Authorised

This medicine is authorised for use in the European Union

pegfilgrastim Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Stimufend](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Stimufend is a medicine used in patients with cancer to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections.

It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (neutropenia accompanied by fever).

Stimufend is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions where large numbers of abnormal blood cells are produced, which can develop into leukaemia).

Stimufend is a 'biosimilar medicine'. This means that Stimufend is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Stimufend is Neulasta. For more information on biosimilar medicines, see [here](/en/biosimilar-medicines-overview) .

Stimufend contains the active substance pegfilgrastim.

Expand section

Collapse section

## How is Stimufend used?

Stimufend can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer or blood disorders.

It is available as a prefilled syringe containing a solution for injection under the skin. Stimufend is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines). Patients can inject themselves if they have been trained appropriately.

For more information about using Stimufend, see the package leaflet or contact your doctor or pharmacist.

## How does Stimufend work?

The active substance in Stimufend, pegfilgrastim, is a form of filgrastim, which is very similar to a human protein called granulocyte colony stimulating factor (G?CSF). Filgrastim works by encouraging the bone marrow to produce more white blood cells, increasing white blood cell counts and so treating neutropenia.

In Stimufend, as in the reference medicine, filgrastim has been 'pegylated' (attached to a chemical called polyethylene glycol). This slows down the removal of filgrastim from the body, allowing the medicine to be given less often.

## What benefits of Stimufend have been shown in studies?

Laboratory studies comparing Stimufend with Neulasta have shown that the active substance in Stimufend is highly similar to that in Neulasta in terms of structure, purity and biological activity. Studies have also shown that giving Stimufend produces similar levels of the active substance in the body to giving Neulasta.

Because Stimufend is a biosimilar medicine, the studies on effectiveness and safety of pegfilgrastim carried out with Neulasta do not all need to be repeated for Stimufend.

## What are the risks associated with Stimufend?

The safety of Stimufend has been evaluated and, on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine Neulasta.

The most common side effect with Stimufend (which may affect more than 1 in 10 people) is pain in the bones. Pain in muscles is also common. For the full list of side effects and restrictions with Stimufend, see the package leaflet.

## Why is Stimufend authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Stimufend has a highly similar structure, purity and biological activity to Neulasta and is distributed in the body in the same way.

All these data were considered sufficient to conclude that Stimufend will behave in the same way as Neulasta in terms of effectiveness and safety in its authorised uses. Therefore, the Agency's view was that, as for Neulasta, the benefits of Stimufend outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Stimufend?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Stimufend have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Stimufend are continuously monitored. Suspected side effects reported with Stimufend are carefully evaluated and any necessary action taken to protect patients.

## Other information about Stimufend

Stimufend received a marketing authorisation valid throughout the EU on 28 March 2022.

Stimufend : EPAR - Medicine Overview

Reference Number: EMA/119299/2022

English (EN) (106.59 KB - PDF)

**First published:** 04/04/2022

[View](/en/documents/overview/stimufend-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-810)

български (BG) (126.54 KB - PDF)

**First published:**

04/04/2022

[View](/bg/documents/overview/stimufend-epar-medicine-overview_bg.pdf)

español (ES) (103.57 KB - PDF)

**First published:**

04/04/2022

[View](/es/documents/overview/stimufend-epar-medicine-overview_es.pdf)

čeština (CS) (124.97 KB - PDF)

**First published:**

04/04/2022

[View](/cs/documents/overview/stimufend-epar-medicine-overview_cs.pdf)

dansk (DA) (102.04 KB - PDF)

**First published:**

04/04/2022

[View](/da/documents/overview/stimufend-epar-medicine-overview_da.pdf)

Deutsch (DE) (105.65 KB - PDF)

**First published:**

04/04/2022

[View](/de/documents/overview/stimufend-epar-medicine-overview_de.pdf)

eesti keel (ET) (90.27 KB - PDF)

**First published:**

04/04/2022

[View](/et/documents/overview/stimufend-epar-medicine-overview_et.pdf)

ελληνικά (EL) (127.1 KB - PDF)

**First published:**

04/04/2022

[View](/el/documents/overview/stimufend-epar-medicine-overview_el.pdf)

français (FR) (104.01 KB - PDF)

**First published:**

04/04/2022

[View](/fr/documents/overview/stimufend-epar-medicine-overview_fr.pdf)

hrvatski (HR) (123.06 KB - PDF)

**First published:**

04/04/2022

[View](/hr/documents/overview/stimufend-epar-medicine-overview_hr.pdf)

italiano (IT) (101.03 KB - PDF)

**First published:**

04/04/2022

[View](/it/documents/overview/stimufend-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (132.36 KB - PDF)

**First published:**

04/04/2022

[View](/lv/documents/overview/stimufend-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (122.9 KB - PDF)

**First published:**

04/04/2022

[View](/lt/documents/overview/stimufend-epar-medicine-overview_lt.pdf)

magyar (HU) (124.86 KB - PDF)

**First published:**

04/04/2022

[View](/hu/documents/overview/stimufend-epar-medicine-overview_hu.pdf)

Malti (MT) (125.57 KB - PDF)

**First published:**

04/04/2022

[View](/mt/documents/overview/stimufend-epar-medicine-overview_mt.pdf)

Nederlands (NL) (103.19 KB - PDF)

**First published:**

04/04/2022

[View](/nl/documents/overview/stimufend-epar-medicine-overview_nl.pdf)

polski (PL) (126.13 KB - PDF)

**First published:**

04/04/2022

[View](/pl/documents/overview/stimufend-epar-medicine-overview_pl.pdf)

português (PT) (103.81 KB - PDF)

**First published:**

04/04/2022

[View](/pt/documents/overview/stimufend-epar-medicine-overview_pt.pdf)

română (RO) (123.37 KB - PDF)

**First published:**

04/04/2022

[View](/ro/documents/overview/stimufend-epar-medicine-overview_ro.pdf)

slovenčina (SK) (123.94 KB - PDF)

**First published:**

04/04/2022

[View](/sk/documents/overview/stimufend-epar-medicine-overview_sk.pdf)

slovenščina (SL) (122.15 KB - PDF)

**First published:**

04/04/2022

[View](/sl/documents/overview/stimufend-epar-medicine-overview_sl.pdf)

Suomi (FI) (100.15 KB - PDF)

**First published:**

04/04/2022

[View](/fi/documents/overview/stimufend-epar-medicine-overview_fi.pdf)

svenska (SV) (100.12 KB - PDF)

**First published:**

04/04/2022

[View](/sv/documents/overview/stimufend-epar-medicine-overview_sv.pdf)

Stimufend : EPAR - Risk management plan summary

English (EN) (211.04 KB - PDF)

**First published:** 04/04/2022

[View](/en/documents/rmp-summary/stimufend-epar-risk-management-plan-summary_en.pdf)

## Product information

Stimufend : EPAR - Product Information

English (EN) (924.32 KB - PDF)

**First published:** 04/04/2022

[View](/en/documents/product-information/stimufend-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-470)

български (BG) (894.32 KB - PDF)

**First published:**

04/04/2022

[View](/bg/documents/product-information/stimufend-epar-product-information_bg.pdf)

español (ES) (1.82 MB - PDF)

**First published:**

04/04/2022

[View](/es/documents/product-information/stimufend-epar-product-information_es.pdf)

čeština (CS) (756.89 KB - PDF)

**First published:**

04/04/2022

[View](/cs/documents/product-information/stimufend-epar-product-information_cs.pdf)

dansk (DA) (999.61 KB - PDF)

**First published:**

04/04/2022

[View](/da/documents/product-information/stimufend-epar-product-information_da.pdf)

Deutsch (DE) (930.58 KB - PDF)

**First published:**

04/04/2022

[View](/de/documents/product-information/stimufend-epar-product-information_de.pdf)

eesti keel (ET) (1.01 MB - PDF)

**First published:**

04/04/2022

[View](/et/documents/product-information/stimufend-epar-product-information_et.pdf)

ελληνικά (EL) (716.45 KB - PDF)

**First published:**

04/04/2022

[View](/el/documents/product-information/stimufend-epar-product-information_el.pdf)

français (FR) (921.01 KB - PDF)

**First published:**

04/04/2022

[View](/fr/documents/product-information/stimufend-epar-product-information_fr.pdf)

hrvatski (HR) (708.96 KB - PDF)

**First published:**

04/04/2022

[View](/hr/documents/product-information/stimufend-epar-product-information_hr.pdf)

íslenska (IS) (841.62 KB - PDF)

**First published:**

04/04/2022

[View](/is/documents/product-information/stimufend-epar-product-information_is.pdf)

italiano (IT) (671.07 KB - PDF)

**First published:**

04/04/2022

[View](/it/documents/product-information/stimufend-epar-product-information_it.pdf)

latviešu valoda (LV) (1.32 MB - PDF)

**First published:**

04/04/2022

[View](/lv/documents/product-information/stimufend-epar-product-information_lv.pdf)

lietuvių kalba (LT) (848.9 KB - PDF)

**First published:**

04/04/2022

[View](/lt/documents/product-information/stimufend-epar-product-information_lt.pdf)

magyar (HU) (1.04 MB - PDF)

**First published:**

04/04/2022

[View](/hu/documents/product-information/stimufend-epar-product-information_hu.pdf)

Malti (MT) (1.23 MB - PDF)

**First published:**

04/04/2022

[View](/mt/documents/product-information/stimufend-epar-product-information_mt.pdf)

Nederlands (NL) (563.91 KB - PDF)

**First published:**

04/04/2022

[View](/nl/documents/product-information/stimufend-epar-product-information_nl.pdf)

norsk (NO) (1.08 MB - PDF)

**First published:**

04/04/2022

[View](/no/documents/product-information/stimufend-epar-product-information_no.pdf)

polski (PL) (665.92 KB - PDF)

**First published:**

04/04/2022

[View](/pl/documents/product-information/stimufend-epar-product-information_pl.pdf)

português (PT) (519.68 KB - PDF)

**First published:**

04/04/2022

[View](/pt/documents/product-information/stimufend-epar-product-information_pt.pdf)

română (RO) (656.52 KB - PDF)

**First published:**

04/04/2022

[View](/ro/documents/product-information/stimufend-epar-product-information_ro.pdf)

slovenčina (SK) (751.84 KB - PDF)

**First published:**

04/04/2022

[View](/sk/documents/product-information/stimufend-epar-product-information_sk.pdf)

slovenščina (SL) (1006.45 KB - PDF)

**First published:**

04/04/2022

[View](/sl/documents/product-information/stimufend-epar-product-information_sl.pdf)

Suomi (FI) (510.98 KB - PDF)

**First published:**

04/04/2022

[View](/fi/documents/product-information/stimufend-epar-product-information_fi.pdf)

svenska (SV) (555.57 KB - PDF)

**First published:**

04/04/2022

[View](/sv/documents/product-information/stimufend-epar-product-information_sv.pdf)

28/03/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Stimufend : EPAR - All authorised presentations

English (EN) (41.23 KB - PDF)

**First published:** 04/04/2022

[View](/en/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-110)

български (BG) (67.99 KB - PDF)

**First published:**

04/04/2022

[View](/bg/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_bg.pdf)

español (ES) (41.74 KB - PDF)

**First published:**

04/04/2022

[View](/es/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_es.pdf)

čeština (CS) (59.07 KB - PDF)

**First published:**

04/04/2022

[View](/cs/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (42.79 KB - PDF)

**First published:**

04/04/2022

[View](/da/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (42.74 KB - PDF)

**First published:**

04/04/2022

[View](/de/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (39.79 KB - PDF)

**First published:**

04/04/2022

[View](/et/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (76.62 KB - PDF)

**First published:**

04/04/2022

[View](/el/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_el.pdf)

français (FR) (40.42 KB - PDF)

**First published:**

04/04/2022

[View](/fr/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (87.34 KB - PDF)

**First published:**

04/04/2022

[View](/hr/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (41.26 KB - PDF)

**First published:**

04/04/2022

[View](/is/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_is.pdf)

italiano (IT) (40.47 KB - PDF)

**First published:**

04/04/2022

[View](/it/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (57.39 KB - PDF)

**First published:**

04/04/2022

[View](/lv/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (58.7 KB - PDF)

**First published:**

04/04/2022

[View](/lt/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (59.46 KB - PDF)

**First published:**

04/04/2022

[View](/hu/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (60 KB - PDF)

**First published:**

04/04/2022

[View](/mt/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (38.53 KB - PDF)

**First published:**

04/04/2022

[View](/nl/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (39.42 KB - PDF)

**First published:**

04/04/2022

[View](/no/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_no.pdf)

polski (PL) (61.17 KB - PDF)

**First published:**

04/04/2022

[View](/pl/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_pl.pdf)

português (PT) (42.36 KB - PDF)

**First published:**

04/04/2022

[View](/pt/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_pt.pdf)

română (RO) (49.59 KB - PDF)

**First published:**

04/04/2022

[View](/ro/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.54 KB - PDF)

**First published:**

04/04/2022

[View](/sk/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (38.96 KB - PDF)

**First published:**

04/04/2022

[View](/sl/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (39.94 KB - PDF)

**First published:**

04/04/2022

[View](/fi/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (38.55 KB - PDF)

**First published:**

04/04/2022

[View](/sv/documents/all-authorised-presentations/stimufend-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Stimufend Active substance pegfilgrastim International non-proprietary name (INN) or common name pegfilgrastim Anatomical therapeutic chemical (ATC) code L03AA13

### Pharmacotherapeutic group

- Immunostimulants
- Colony stimulating factors

### Therapeutic indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

## Authorisation details

EMA product number EMEA/H/C/004780

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Fresenius Kabi Deutschland GmbH

Else-Kröner-Straße 1,

Opinion adopted 27/01/2022 Marketing authorisation issued 28/03/2022

## Assessment history

## Initial marketing authorisation documents

Stimufend : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/98697/2022

English (EN) (3.04 MB - PDF)

**First published:** 04/04/2022

[View](/en/documents/assessment-report/stimufend-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Stimufend

Adopted

Reference Number: EMA/CHMP/18376/2022

English (EN) (124.47 KB - PDF)

**First published:** 28/01/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-stimufend_en.pdf)

#### News on Stimufend

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022) 28/01/2022

**This page was last updated on** 04/04/2022

## Share this page

[Back to top](#main-content)